Related Experiment Video

Updated: Apr 30, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.3K

Gene polymorphisms associated with susceptibility to coronary artery disease in Han Chinese people

Y H Liu1, Y W Zhou2, J A Yang3

  • 1Department of Laboratory Medicine, Sun Yat-sen Cardiovascular Hospital, Shenzhen, Guangdong, China.

Genetics and Molecular Research : GMR
|May 1, 2014
PubMed

Insights

This study identifies specific single nucleotide polymorphism (SNP) haplotypes linked to coronary artery disease (CAD) risk in the Chinese Han population. Certain SNP variations, like rs10757278G, increase CAD risk, while others offer protection.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Population Genetics

Background:

  • Coronary artery disease (CAD) is a significant health concern globally.
  • Identifying genetic susceptibility factors is crucial for understanding CAD pathogenesis.
  • Previous research has implicated various genes in CAD development, necessitating further investigation in diverse populations.

Purpose of the Study:

  • To investigate the association of 5 single nucleotide polymorphism (SNP) haplotypes in CAD susceptibility genes with CAD in the Chinese Han population.
  • To determine the specific roles of individual SNPs and their combined effects (haplotypes) in CAD risk.
  • To explore potential correlations between identified genetic factors and clinical parameters like glucose levels and hypertension.

Main Methods:

  • Case-control study involving 119 CAD patients and 115 healthy controls from the Chinese Han population.
  • Genotyping of selected SNPs using multiplex SNaP-shot technology.
  • Statistical analysis including odds ratio (OR) and confidence interval (CI) calculations to assess the risk and protective effects of SNPs and haplotypes.

Main Results:

  • The HNRPUL1 gene rs11881940T and GATA2 gene rs3803T loci showed significant correlation with CAD.
  • The SNP rs10757278G was identified as a risk factor for CAD (OR = 1.242).
  • SNPs rs11881940T and rs3803T acted as protective factors (ORs = 0.767 and 0.53, respectively).
  • Haplotypes ATC, GAC, and GAT were associated with increased CAD risk, while GTC was protective.
  • The ATC haplotype showed a positive correlation with glucose levels, and the GAT haplotype was a risk factor for hypertension.

Conclusions:

  • Polymorphisms and haplotype analysis of CAD susceptibility genes are valuable for improving CAD prediction.
  • The identified SNPs and haplotypes can aid in the early diagnosis of coronary artery disease.
  • Genetic profiling may offer personalized risk assessment for cardiovascular diseases.

More Related Videos

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

23.8K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.6K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121